Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study

Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study

Abstract Background In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial) treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin significantly reduced heart failure hospitalization (HHF) in patients with type 2 diabetes mellitus (T2D) and establi...

Full description

Bibliographic Details
Main Authors: Matthias Rau, Kirsten Thiele, Niels-Ulrik Korbinian Hartmann, Alexander Schuh, Ertunc Altiok, Julia Möllmann, András P. Keszei, Michael Böhm, Nikolaus Marx, Michael Lehrke
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Cardiovascular Diabetology
Subjects:
SGLT2 inhibitors
Diabetes
Diastolic function
Hemodynamic parameters
Online Access:https://doi.org/10.1186/s12933-020-01175-5

Internet

https://doi.org/10.1186/s12933-020-01175-5

Similar Items